This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Systemic -Interferon in Multiple Sclerosis

Long-term Patient Follow-up

Hillel S. Panitch, MD

Arch Neurol. 1987;44(1):61-63.

Abstract
• Twelve patients with relapsing multiple sclerosis who had participated in a clinical trial of systemic (subcutaneous) natural -interferon were interviewed and reexamined 4.3 years after beginning interferon treatment and 2.3 years after completion of the study. There was a progressive reduction in exacerbation rate from 1.33 per year to 0.47 per year. Overall neurologic function and disability did not change significantly. Six patients stabilized or improved, and were able to carry on normal daily activities. There were no long-term deleterious side effects. These results are similar to those described for patients treated with intrathecal β-interferon. The mechanism of the prolonged beneficial effect is unknown, but is unlikely to represent antiviral activity in the central nervous system, and more probably involves systemic immunoregulatory functions. The systemic route of administration of interferon may be as effective as the intrathecal route in multiple sclerosis, and is potentially less hazardous.

Author Affiliations
From the Department of Neurology, University of Maryland, Baltimore.

Footnotes
Accepted for publication Sept 2, 1986.

Reprint requests to Department of Neurology, University of Maryland, 22 S Greene St, Baltimore, MD 21201 (Dr Panitch).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
Jacobs and Johnson
Arch Neurol 1994;51:1245-1252.
ABSTRACT  

Exacerbation of Multiple Sclerosis After the Administration of Recombinant Human Interferon Alfa
Larrey et al.
JAMA 1989;261:2065-2065.
ABSTRACT  

Systemic Interferon Alfa in Multiple Sclerosis
Weinshenker and Ebers
Arch Neurol 1989;46:251-252.
ABSTRACT  

Systemic Interferon Alfa in Multiple Sclerosis-Reply
Panitch
Arch Neurol 1989;46:252-252.
ABSTRACT